Human umbilical cord mesenchymal stromal cells (hUC-MSCs) of Wharton's jelly origin undergo adipogenic, osteogenic, and chondrogenic differentiation in vitro. Recent studies have consistently shown their therapeutic potential in various human disease models. However, the biological effects of major pregnancy complications on the cellular properties of hUC-MSCs remain to be studied. In this study, we compared the basic properties of hUC-MSCs obtained from gestational diabetes mellitus (GDM) patients (GDM-UC-MSCs) and normal pregnant women (N-UC-MSCs). Assessments of cumulative cell growth, MSC marker expression, cellular senescence, and mitochondrial function-related gene expression were performed using a cell count assay, senescence-associated β-galactosidase staining, quantitative real-time reverse transcription–polymerase chain reaction, immunoblotting, and cell-based mitochondrial functional assay system. When compared with N-UC-MSCs, GDM-UC-MSCs showed decreased cell growth and earlier cellular senescence with accumulation of p16 and p53, even though they expressed similar levels of CD105, CD90, and CD73 MSC marker proteins. GDM-UC-MSCs also displayed significantly lower osteogenic and adipogenic differentiation potentials than N-UC-MSCs. Furthermore, GDM-UC-MSCs exhibited a low mitochondrial activity and significantly reduced expression of the mitochondrial function regulatory genes ND2, ND9, COX1, PGC-1α, and TFAM. Here, we report intriguing and novel evidence that maternal metabolic derangement during gestation affects the biological properties of fetal cells, which may be a component of fetal programming. Our findings also underscore the importance of the critical assessment of the biological impact of maternal–fetal conditions in biological studies and clinical applications of hUC-MSCs.
Get full access to this article
View all access options for this article.
References
1.
ThomsonJA, Itskovitz-EldorJ, ShapiroSS, WaknitzMA, SwiergielJJ, MarshallVS and JonesJM. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282:1145–1147.
2.
de LazaroI, YilmazerA and KostarelosK. (2014). Induced pluripotent stem (iPS) cells: a new source for cell-based therapeutics?. J Control Release, 185c:37–44.
3.
WeissML, AndersonC, MedicettyS, SeshareddyKB, WeissRJ, VanderWerffI, TroyerD and McIntoshKR. (2008). Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells, 26:2865–2874.
4.
TroyerDL and WeissML. (2008). Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells, 26:591–599.
5.
KimDW, StaplesM, ShinozukaK, PantchevaP, KangSD and BorlonganCV. (2013). Wharton's jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci, 14:11692–11712.
6.
LianQ, LyeE, Suan YeoK, Khia Way TanE, Salto-TellezM, LiuTM, PalanisamyN, El OakleyRM, LeeEH, LimB and LimSK. (2007). Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells, 25:425–436.
7.
AnzaloneR, Lo IaconoM, LoriaT, Di StefanoA, GiannuzziP, FarinaF and La RoccaG. (2011). Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev, 7:342–363.
8.
WeissML and TroyerDL. (2006). Stem cells in the umbilical cord. Stem Cell Rev, 2:155–162.
9.
WeissML, MedicettyS, BledsoeAR, RachakatlaRS, ChoiM, MerchavS, LuoY, RaoMS, VelagaletiG and TroyerD. (2006). Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells, 24:781–792.
10.
MaS, LiangS, JiaoH, ChiL, ShiX, TianY, YangB and GuanF. (2014). Human umbilical cord mesenchymal stem cells inhibit C6 glioma growth via secretion of dickkopf-1 (DKK1). Mol Cell Biochem, 385:277–286.
11.
GauthamanK, YeeFC, CheyyatraivendranS, BiswasA, ChoolaniM and BongsoA. (2012). Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro. J Cell Biochem, 113:2027–2039.
12.
HarrisDT. (2013). Umbilical cord tissue mesenchymal stem cells: characterization and clinical applications. Curr Stem Cell Res Ther, 8:394–399.
13.
LakshmyR. (2013). Metabolic syndrome: role of maternal undernutrition and fetal programming. Rev Endocr Metab Disord, 14:229–240.
14.
ThornburgKL, O'TierneyPF and LoueyS. (2010). Review: the placenta is a programming agent for cardiovascular disease. Placenta, 31Suppl:S54–S59.
15.
FerraraA. (2007). Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care, 30Suppl 2:S141–S146.
16.
SchwartzR, GruppusoPA, PetzoldK, BrambillaD, HiilesmaaV and TeramoKA. (1994). Hyperinsulinemia and macrosomia in the fetus of the diabetic mother. Diabetes Care, 17:640–648.
17.
PedersenJ. (1952). Diabetes and pregnancy; blood sugar of newborn infants during fasting and glucose administration. Nord Med, 47:1049.
18.
NomuraY, LambertiniL, RialdiA, LeeM, MystalEY, GrabieM, ManasterI, HuynhN, FinikJ, et al. (2014). Global methylation in the placenta and umbilical cord blood from pregnancies with maternal gestational diabetes, preeclampsia, and obesity. Reprod Sci, 21:131–137.
19.
MetzgerBE, GabbeSG, PerssonB, BuchananTA, CatalanoPA, DammP, DyerAR, LeivaA, HodM, et al. (2010). International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care, 33:676–682.
20.
RedlineRW. (2008). Placental pathology: a systematic approach with clinical correlations. Placenta, 29Suppl A:S86–S91.
21.
PiaoY, KimHG, OhMS and PakYK. (2012). Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP(+)-induced mitochondrial dysfunctions in neuronal cells. Biochim Biophys Acta, 1820:577–585.
22.
LeeJS, LeeMO, MoonBH, ShimSH, FornaceAJJr. and ChaHJ. (2009). Senescent growth arrest in mesenchymal stem cells is bypassed by Wip1-mediated downregulation of intrinsic stress signaling pathways. Stem Cells, 27:1963–1975.
23.
ZhuY, SunZ, HanQ, LiaoL, WangJ, BianC, LiJ, YanX, LiuY, ShaoC and ZhaoC. (2009). Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia, 23:925–933.
24.
KooHJ, PiaoY and PakYK. (2012). Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals, 20:265–280.
25.
BirketMJ, OrrAL, GerencserAA, MaddenDT, VitelliC, SwistowskiA, BrandMD and ZengX. (2011). A reduction in ATP demand and mitochondrial activity with neural differentiation of human embryonic stem cells. J Cell Sci, 124:348–358.
26.
SinghM and PiekorzRP. (2013). Senescence-associated lysosomal alpha-L-fucosidase (SA-alpha-Fuc): a sensitive and more robust biomarker for cellular senescence beyond SA-beta-Gal. Cell Cycle, 12:1996.
27.
KimWY and SharplessNE. (2006). The regulation of INK4/ARF in cancer and aging. Cell, 127:265–275.
28.
SerranoM, LinAW, McCurrachME, BeachD and LoweSW. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88:593–602.
29.
JonesCJ, KiplingD, MorrisM, HepburnP, SkinnerJ, BounacerA, WyllieFS, IvanM, BartekJ, Wynford-ThomasD and JABond. (2000). Evidence for a telomere-independent “clock”. limiting RAS oncogene-driven proliferation of human thyroid epithelial cells. Mol Cell Biol, 20:5690–5699.
30.
HerbigU, JoblingWA, ChenBP, ChenDJ and SedivyJM. (2004). Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell, 14:501–513.
PengL, JiaZ, YinX, ZhangX, LiuY, ChenP, MaK and ZhouC. (2008). Comparative analysis of mesenchymal stem cells from bone marrow, cartilage, and adipose tissue. Stem Cells Dev, 17:761–773.
33.
OdeA, SchoonJ, KurtzA, GaetjenM, OdeJE, GeisslerS and DudaGN. (2013). CD73/5′-ecto-nucleotidase acts as a regulatory factor in osteo-/chondrogenic differentiation of mechanically stimulated mesenchymal stromal cells. Eur Cell Mater, 25:37–47.
34.
PetersenKF, BefroyD, DufourS, DziuraJ, AriyanC, RothmanDL, DiPietroL, ClineGW and ShulmanGI. (2003). Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science, 300:1140–1142.
35.
LeeHY, ChoiCS, BirkenfeldAL, AlvesTC, JornayvazFR, JurczakMJ, ZhangD, WooDK, ShadelGS, et al. (2010). Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. Cell Metab, 12:668–674.
36.
DimauroS and DavidzonG. (2005). Mitochondrial DNA and disease. Ann Med, 37:222–232.
37.
NichollsDG, Darley-UsmarVM, WuM, JensenPB, RogersGW and FerrickDA. (2010). Bioenergetic profile experiment using C2C12 myoblast cells. J Vis Exp (46):pii 2511.
38.
LiuY, LiZ, LiuT, XueX, JiangH, HuangJ and WangH. (2013). Impaired cardioprotective function of transplantation of mesenchymal stem cells from patients with diabetes mellitus to rats with experimentally induced myocardial infarction. Cardiovasc Diabetol, 12:40.
39.
KrishnamurthyJ, RamseyMR, LigonKL, TorriceC, KohA, Bonner-WeirS and SharplessNE. (2006). p16INK4a induces an age-dependent decline in islet regenerative potential. Nature, 443:453–457.
40.
YuKR and KangKS. (2013). Aging-related genes in mesenchymal stem cells: a mini-review. Gerontology, 59:557–563.
BainesHL, TurnbullDM and GreavesLC. (2014). Human stem cell aging: do mitochondrial DNA mutations have a causal role?. Aging Cell, 13:201–205.
43.
NooteboomM, JohnsonR, TaylorRW, WrightNA, LightowlersRN, KirkwoodTB, MathersJC, TurnbullDM and GreavesLC. (2010). Age-associated mitochondrial DNA mutations lead to small but significant changes in cell proliferation and apoptosis in human colonic crypts. Aging Cell, 9:96–99.
44.
BernsteinC, FacistaA, NguyenH, ZaitlinB, HassounahN, LoustaunauC, PayneCM, BanerjeeB, GoldschmidS, et al. (2010). Cancer and age related colonic crypt deficiencies in cytochrome c oxidase I. World J Gastrointest Oncol, 2:429–442.
45.
TrifunovicA, WredenbergA, FalkenbergM, SpelbrinkJN, RovioAT, BruderCE, BohloolyYM, GidlofS, OldforsA, et al. (2004). Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature, 429:417–423.
46.
KujothGC, HionaA, PughTD, SomeyaS, PanzerK, WohlgemuthSE, HoferT, SeoAY, SullivanR, et al. (2005). Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science, 309:481–484.
47.
WuG, Imhoff-KunschB and GirardAW. (2012). Biological mechanisms for nutritional regulation of maternal health and fetal development. Paediatr Perinat Epidemiol, 26Suppl 1:4–26.
MeierRP, MullerYD, MorelP, Gonelle-GispertC and BuhlerLH. (2013). Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence?. Stem Cell Res, 11:1348–1364.
50.
BreitbachM, BostaniT, RoellW, XiaY, DewaldO, NygrenJM, FriesJW, TiemannK, BohlenH, et al. (2007). Potential risks of bone marrow cell transplantation into infarcted hearts. Blood, 110:1362–1369.
51.
di BonzoLV, FerreroI, CravanzolaC, MareschiK, RustichellD, NovoE, SanavioF, CannitoS, ZamaraE, et al. (2008). Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut, 57:223–231.
52.
KlinkhammerBM, KramannR, MallauM, MakowskaA, van RoeyenCR, RongS, BuecherEB, BoorP, KovacovaK, et al. (2014). Mesenchymal stem cells from rats with chronic kidney disease exhibit premature senescence and loss of regenerative potential. PLoS One, 9:e92115.
53.
MantovaniC, RaimondoS, HaneefMS, GeunaS, TerenghiG, ShawcrossSG and WibergM. (2012). Morphological, molecular and functional differences of adult bone marrow- and adipose-derived stem cells isolated from rats of different ages. Exp Cell Res, 318:2034–2048.
54.
GeisslerS, TextorM, KuhnischJ, KonnigD, KleinO, OdeA, PfitznerT, AdjayeJ, KasperG and DudaGN. (2012). Functional comparison of chronological and in vitro aging: differential role of the cytoskeleton and mitochondria in mesenchymal stromal cells. PLoS One, 7:e52700.
55.
MoonHE, YoonSH, HurYS, ParkHW, HaJY, KimKH, ShimJH, YooSH, SonJH, et al. (2013). Mitochondrial dysfunction of immortalized human adipose tissue-derived mesenchymal stromal cells from patients with Parkinson's disease. Exp Neurobiol, 22:283–300.
